Current Projects

International

Protizápalový účinok prírodných látok izolovaných z vietnamských liečivých rastlín
Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
Program: Bilateral – other
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration:
ONTOX – Testovanie opakovanej toxicity chemických látok na základe ontológie a umelej inteligencie za účelom hodnotenia rizík metódami NGRA
Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment
Program: Horizon 2020
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation: The vision of the ONTOX project is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next-generation risk assessment. Specifically, ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon the combination with tailored exposure assessment, will enable human risk assessment. This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect. However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors. The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/mechanistic, toxicological/ epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing. The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence. This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation. ONTOX will have a deep and long-lasting impact at many levels, in particular by consolidating Europe\’s world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals.
Project web page: www.ontox-project.eu
Duration: 1.5.2021 – 1.5.2026
EU-NETVAL Medzinárodná validačná štúdia tyroidnej disrupcie
EU-NETVAL International Thyroid Validation Study
Program: Multilateral – other
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation: Characterising, validating and standardising new non-animal methods and approaches are important steps towards their regulatory use and international adoption. Various thyroid methods, targeting different modes of action of thyroid disruption, are currently under validation by EURL ECVAM and its network of validation laboratories EU-NETVAL. Chemicals that disrupt thyroid homeostasis have the potential to be endocrine disruptors and thus associated with several adverse health effects.About EU-NETVAL:EU-NETVAL is a large network of 39 highly qualified test facilities across Europe, coordinated by the JRC to support the in vitro method validation process. It represents a wide range of expertise and competences and includes laboratories experienced in advanced in vitro procedures, biological test systems and measurement techniques.
Project web page: https://ec.europa.eu/jrc/en/eurl/ecvam/alternative-methods-toxicity-testing/eu-netval
Duration: 1.1.2021 – 1.1.2023
Protizápalový účinok prírodných látok izolovaných z vietnamských liečivých rastlín
Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
Program: Bilateral – other
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration: 1.1.2020 – 31.12.2022
LOGIC LAB – Molecular logic lab-on-a-vesicle for intracellular diagnostics
Molecular logic lab-on-a-vesicle for intracellular diagnostics
Program: Horizon 2020
Project leader: RNDr. Mach Mojmír PhD.
Annotation: A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related diseases. According to the WHO, those diseases accounted for 60% of all deaths worldwide in 2005. Tailor-made diagnostic tools for early and reliable identification of endothelial dysfunction are urgently needed both in fundamental research and clinical routine, respectively.The Marie Skłodowska-Curie action LOGIC LAB objects to develop and characterize innovative molecular logic gates that can be applied as advanced diagnostic tools for parallel analyte sensing in live mammalian cells. Thereby, providing a unique method to discover endothelial dysfunction and the onset of diseases much easier and earlier than so far.LOGIC LAB creates a multi-faceted and multi-sectoral research environment for the next generation of scientists in order to establish a novel type of molecular logic sensors that reliably operate in biological media – a crucial requirement for their application i.e. as rapid and easy-to-handle tools for intracellular diagnostics.With excellent cross-disciplinary scientific and complementary training provided in the network, we aim to educate highly-skilled young scientists in the fields of chemistry, physics and biology, who will significantly strengthen the international research community in the domain of molecular logic sensing. Thus, in the long term, LOGIC LAB aims to finally bridge the gap between lab bench and biological or medical practice. It is this gap, that so far prevents a wide-ranging use of existing molecular logic gates e.g. for the diagnosis of lifestyle-associated diseases.
Duration: 1.11.2018 – 31.10.2022
CardioRNA – Katalýza transkriptomického výskumu kardiovaskulárnych ochorení
Catalysing transcriptomic research in cardiovascular disease
Program: COST
Project leader: doc. RNDr. Barteková Monika PhD.
Duration: 3.10.2018 – 2.10.2022
Train -SafeMDs – Školiaca sieť zameraná na zvýšenie bezpečnosti zdravotníckych pomôcok – fokus na ústnu dutinu
Training Network for improving of safety of medical devices – focus on oral cavity
Program: Multilateral – other
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation: The TraiN-SafeMDs (i.e. Training Network for improving knowledge on the safety of medical devices) project brings together the unique expertise of the Czech National Institute of Public Health located in Prague (NIPH), the expertise of the Centre of Experimental Medicine in Bratislava (CEM) and the Austrian Institute of Technology in Vienna (AIT). The research team of the project has extensive expertise in tissue engineering of models of oral epithelium and/or in safety testing of different MD materials. The project also aims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Project web page: https://www.medicaldevicessafety.com/
Duration: 1.1.2020 – 31.8.2022
Anti-inflammatory effect of astaxanthin, sulforaphane and Crocus sativus extract evaluated in two rodent models of age related diseases.
Program: Inter-academic agreement
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration: 1.1.2018 – 31.12.2021
SKPTPHARMACOL – Spolupráca na komplexnom hodnotení farmakologického ovplyvnenia zápalových ochorení pohybového aparátu a gastrointestinálneho traktu na experimentálnych zvieracích modeloch
Collaboration on a complex pharmacological assessment of inflammatory diseases of the musculo-skeletal system and gastrointestinal tract on experimental animal models
Program: Bilateral – other
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Duration: 1.1.2019 – 31.12.2021
EU-CARDIOPROTECT – Realizácia terapeutického potenciálu nových kardioprotektívnych terapií
Realising the therapeutic potential of novel cardioprotective therapies
Program: COST
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation: The proposed COST Action will set up a pan-European Research Network of leading experts in cardioprotection, to jointly develop new initiatives and new strategies for finding innovative and more effective approaches to cardioprotection and for optimizing the pre-clinical and clinical evaluation of new cardioprotective therapies, so as to improve their translation into the clinical setting for patient benefit. The COST Action will co-ordinate and strengthen European research in the field of cardioprotection and accelerate scientific progress through the dissemination and sharing of new therapeutic targets, among network members and industrial partners, thereby facilitating the discovery of new cardioprotective therapies. By utilizing the joint expertise of different European network members we will investigate factors which confound the efficacy of new cardioprotection therapies including comorbidities (such as age, diabetes, and hypertension) and co-medications (such as anti-platelet therapies, statins and beta-blockers). Finally, we will set up a European network of research centers for multi-center laboratory testing of new cardioprotective therapies using small and large animal models of acute IRI in order to select those therapies most likely to succeed in the clinical setting. All aspects of this COST Action proposal require a critical mass of partners across a wide geographic distribution across Europe in order to deliver the objectives outlined in this proposal. The discovery of novel signaling pathways and targets underlying cardioprotection both within and outside the cardiomyocyte (WG1 NEW TARGETS), and the testing of different combinations of cardioprotective therapy (WG2 COMBINATION THERAPY) requires investigators with different experience and expertise across Europe. The ability to test the effect of confounders of cardioprotection (WG3 CONFOUNDERS) requires the expertise of different partners in the different co-morbidities and testing of co-medications. Finally, the most important objective of this COST Action proposal, requires the setting up of a Europe-wide research network for (a) multicenter testing of novel cardioprotective therapies using small and large animal models (WG4 CONSORTIUM) and (b) testing of novel cardioprotective therapies in proof-of-concept clinical studies and optimization of multi-center clinical outcome cardioprotection studies. By definition this requires a critical mass of research partners distributed across Europe.
Duration: 19.10.2017 – 18.10.2021

National

Kardioprotektívny potenciál TRP kanálov: úloha v remodelácii, zápale a vápnikovej dysregulácii
Program: VEGA
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Duration: 1.1.2021 – 31.12.2024
Úloha makroautofágie a autofágie sprostredkovanej šaperónmi (CMA) v odpovediach a v adaptácii živočíšnych buniek na účinky vyvolané pôsobením doxorubicínu
The role of macroautophagy and chaperone-mediated autophagy (CMA) in the responses and adaptation of animal cells to doxorubicin-induced effects
Program: VEGA
Project leader: RNDr. Barančík Miroslav DrSc.
Duration: 1.1.2021 – 31.12.2024
Vlastnosti erytrocytov a oxidačný stres za vybraných patológií a po podávaní antioxidantov
Program: VEGA
Project leader: RNDr. Vrbjar Norbert CSc.
Duration: 1.1.2021 – 31.12.2024
Safe-MDs – In vitro hodnotenie bio-kompatibility zdravotníckych pomôcok (ZP) a inovatívnych bio-materiálov pre ZP
In vitro biocompatibility testing of medical devices (MDs) and new generation bio-materials for MDs
Program: SRDA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation: Medical devices (MDs) have an irreplaceable role in the healthcare of the 21st century. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MD must not cause adverse effects and must demonstrate bio-compatibility with the tissues in the patient’s body.Most of the MDs\’ bio-compatibility assessments are still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress of validation of alternative methods, the MD regulations also utilize in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed human epidermis (RhE) test for intra-cutaneous testing into the ISO standard 10993-23.The presented research proposal focuses on the development of in vitro methods for biocompatibility assessment of medical devices (MDs) and innovative materials to be used as MDs polymers and that are intended for the use in the oral and vaginal cavities or on/in ocular epithelium.
Duration: 1.7.2020 – 30.6.2024
SEMSTIM – Kognitívne a mozgové mechanizmy sémantického spracovania informácií
Cognitive and brain mechanisms of semantic processing
Program: SRDA
Project leader: MUDr. Riečanský Igor PhD.
Duration: 1.7.2020 – 30.6.2024
HNOSES – Štúdium biologických účinkov produktov H2S/NO/selénovej interakcie a molekulárne mechanizmy ich pôsobenia
Study of biological effects of H2S/NO/selenium products and molecular mechanisms of their actions
Program: SRDA
Project leader: RNDr. Čačányiová Soňa PhD.
Annotation: Reactive sulfur (RSS), nitrogen (RNS) and selenium species (RSEs) are groups of simple chemical molecules ofradical or non-radical nature, which interact with cellular components and thereby influence various biologicalprocesses. The study of biological effects of RSS, RNS and RSeS and their mutual interactions is important for theunderstanding of their biological roles, moreover for the potential application of these species in medicine. Ourstudies of the reactive species interaction in the last 3 years showed that:- products of hydrogen sulfide (H2S) and polysulfides (H2Sn, n≥2) interaction with nitric oxide (NO) or seleniumcompounds (R-Se) significantly affect oxygen radicals concentrations, hydroperoxide cleavage, DNA damage, ratblood pressure and tension/relaxation of isolated aorta.- H2S and H2S2 interact with tetracycline antibiotics, mainly doxycycline (DOXY) and thereby produce/inhibitsuperoxide and hydroxyl radicals and induce/inhibit DNA damageThese findings imply the possibility that reactive oxygen species (ROS) and other H2S/NO/R-Se interactionproducts affect (patho)physiological functions in living organisms. In the project´s aims we will build on the previousfindings and investigate following new hypotheses:1) Do mixtures (H2Sn/R-Se, H2Sn/R-Se/NO alebo H2Sn/DOXY) produce ROS or other biologically activecompounds?2) Are these products responsible for production/inhibition of radicals, cleavage of hydroperoxides andinduction/inhibition of DNA damage?3) Do interaction products affect ferroptosis or intracellular calcium concentration in cells?4) Do these products affect rat blood pressure, arterial pulse waveform and tension of isolated arteries?The aim of this project is to investigate the chemical biology, activity and effects of the interaction products oncellular, organ and whole-organism level. These findings may contribute to the development of novel therapeuticinterventions based on the modulation of cellular redox biology.
Duration: 1.7.2020 – 30.6.2024
MIRCVD – Úloha miRNA pri vzniku a priebehu kardiovaskulárnych ochorení – nové prístupy ochrany srdca v situáciách zvýšenej produkcie reaktívnych foriem kyslíka
The role of miRNAs in the onset and progression of cardiovascular diseases – new approach to the protection of the heart in situations of increased production of reactive oxygen species
Program: SRDA
Project leader: Mgr. Kura Branislav PhD.
Annotation: Despite progress in prevention, diagnosis and treatment, cardiovascular disease (CVD) is one of the highest morbidity and mortality rates in the world. World Health Organization statistics suggest that in 2030 approximately 23.6 million people will die of CVD, particularly from heart failure and myocardial infarction. One of the most common causes of many CVDs is excessive production of reactive oxygen species (ROS). These arise naturally in all organisms that gain energy by oxidizing substrates, but are also the result of various exogenous effects, such as radiation or air pollution. ROSs affect all types of cells in the body. By their activity, they cleave electrons from the molecules, making the surrounding molecules unstable and subsequently damaging other surrounding molecules. This damage process leads to cell apoptosis, tissue damage and pathological processes and diseases. At present, many experimental works emphasize the use of microRNAs (miRNAs) in diagnostics and potentially also in CVD therapy. miRNA is a group of short non-coding RNAs that, upon binding to a protein mRNA chain, inhibit its synthesis, greatly affecting many processes in the body. ROS production and the effect of miRNA expression are linked to the development of many CVDs, so it is important to understand the relationship between these factors. Research into new suitable substances and methods that can positively affect the effects of excessive ROS formation on the cardiovascular system can significantly improve the quality of life of cardiological patients. The aim of the project is to look for suitable substances that will prevent toxic effects of excessively formed ROS and positively affect the mechanisms that cause damage. At the same time, elucidation of the role of miRNA involvement in signaling pathways associated with the action of ROS on the development and progression of various CVDs is also be presented.
Duration: 1.7.2020 – 30.6.2024
NEISAD – Úloha neischemických adaptačných stimulov v ochrane ischemického myokardu: štúdium spúšťacích mechanizmov a bunkovej kardioprotektívnej signalizácie.
The role of non-ischemic adaptive stimuli in protection of ischemic myocardium: study of triggering mechanisms and cardioprotective cell signaling
Program: SRDA
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation: Cardiovascular diseases, especially ischemic heart disease (IHD) as a leading cause of heart failure and mortalityworldwide, will not reduce over the coming decades despite the progress in pharmacotherapy, interventionalcardiology and surgery. It is due to aging population and longer survival after acute myocardial infarction (MI),gradual decline of its function and incidence of comorbidities (diabetes, hypertension, dyslipidemia). Experimentalstudies revealed attenuation of MI by adaptive phenomenon of ischemic “conditioning“. However, it is not usuallyapplicable in clinical medicine. In line with translation-oriented research, the project is aimed to: 1. verify theefficiency of cardioprotection induced by non-ischemic stimuli, such as motoric activity, hypoxia and non-invasiveremote “conditioning“; 2. identify triggering mechanisms and pathways of signal transduction (“survival” cascadesRISK and SAFE) to the target structures involved in heart injury reduction (mitochondrial permeability transitionVV 2019 Základný výskumAPVV-19-0540Akronym: NEISAD 06.07.2020 10:48 Strana/Page: 2pore, MPTP, nuclear PPAR receptors); 3. investigate the impact of comorbidities, age and gender on the adaptiveprocesses considering functional, structural and subcellular cardiac alterations. Special emphasis will be placed onthe role of small non-coding RNA (miRNA) regulating cell “survival” pathways and processes of apoptosis andnecroptosis associated with cell oxidative state and Ca2+ homeostasis. We will focus on disclosure of the benefitsof combination therapy: pleiotropic effects of PPAR agonists, MPTP inhibitors, coupled with noninvasive adaptiveinterventions not only under normal but also under pathological conditions (hypertension, hyperlipidemia,hyperglycemia). On animal in vivo and ex vivo models, combination of physiological, biochemical, selectedbiophysical and molecular biology methods will enable to elucidate processes of heart failing/regeneration and gainresults that may lead to development of novel/modified strategies of IHD management.
Duration: 1.7.2019 – 30.6.2024
Centrum pre biomedicínsky výskum – BIOMEDIRES – II. etapa
Centre for biomedical research – BIOMEDIRES – II. stage
Program: EU Structural Funds Research & Development
Project leader: doc. RNDr. Pecháňová Oľga DrSc.
Duration: 12.3.2020 – 11.3.2024
Prenatálne programovanie chorôb v dospelosti: možnosti terapie a prevencie následkov prenatálnej hypoxie u potomstva potkanov
Prenatal programming of adult diseases: treatment and prevention of outcomes of gestational hypoxia in rat offspring
Program: VEGA
Project leader: RNDr. Mach Mojmír PhD.
Annotation: Hypoxia during pregnancy, labor or early life stage is a major determinant of neurological morbidity and mortality in the neonatal period. In the last decade the fetal origin of chronic adult diseases was proposed as the most important factor in genesis of diabetes and hypertension in adulthood. The scientists showed that malnutrition, and inadequate oxygen supply during embryofetal development may lead to the inadequate apoptosis/necrosis, and caused maldevelopment of the organs responsible for regulation blood pressure, glucose, or improper brain wiring. Although the understanding of perinatal asphyxia-related pathophysiology is gradually increasing, limited therapeutic options are available to prevent or even mitigate the devastating process that unfolds after injury. Mitochondria-targeted antioxidants (MTA) are one of the most important therapies for providing neuroprotection in cerebral ischemia. The aim of the project will be to explore the possibilities of using MTA in late gestational hypoxia model.
Duration: 1.1.2020 – 31.12.2023
Experimentálna liečba neonatálnej hypoxicko-ischemickej encefalopatie (nHIE): potenciácia hypotermickej neuroprotekcie melatonínom u novorodených potkanov
Experimental therapy of neonatal hypoxic-ischemic encephalopathy (nHIE): potentiation of hypothermic neuroprotection by melatonin in newborn rats
Program: VEGA
Project leader: RNDr. Juránek Ivo PhD., DrSc.
Annotation: Neonatal hypoxic-ischemic encephalopathy (nHIE) is among most serious causes of mortality and morbidity in newborns. Efficacy of current nHIE treatment is rather low. Routinely used therapeutic hypothermia (HT) is only partially effective. To augment hypothermic neuroprotection, drugs like erythropoietin, anticonvulsants, antioxidants and inert gases are tested. In this project, using newborn rats, we will study possible augmentation of hypothermia effect by combining HT with melatonin (MEL)-derived antioxidants. We will assess brain damage and efficacy of each intervention by various techniques, including noninvasive in vivo MRI and MRS, histology and neurobehavioral testing. Novelty of the project lies in testing our idea that MEL-derivative possessing antioxidative properties 100 fold higher than MEL will be more effective in potentiating the hypothermic effect than MEL itself. Anticipated results may help understand better nHIE mechanisms and to propose new strategies to treat birth asphyxia effectively.
Duration: 1.1.2020 – 31.12.2023
Hodnotenie biologickej kompatibility zdravotníckych pomôcok (ZP) a innovativnych materiálov pre výrobu ZP s využitím in vitro metód založených na 3D rekonštruovaných modeloch ľudského tkaniva.
Bio-compatibility assessment of medical devices and novel medical device materials using in vitro methods based on 3D reconstructed human tissue models.
Program: VEGA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Duration: 1.1.2020 – 31.12.2023
Podieľajú sa konexinové kanály v preťaženom srdcovom svale na extracelulárnej remodelácii?
Are connexin channels involved in extracellular matrix remodeling of overloaded heart?
Program: VEGA
Project leader: RNDr. Tribulová Narcisa DrSc.
Annotation: Cardiac connexin (Cx) channels that are localized at the gap junctions in intercalated discs ensure electrical and molecular signals propagation among cardiomyocytes. Such direct intercellular signaling is essential for synchronized heart contraction. Cardiovascular diseases in humans as well as in animal models are accompanied by abnormal Cx43 expression and its enhanced localization to the lateral sides of the cardiomyocytes. Consequently, it deteriorates synchronized heart function and increase a risk for malignant arrhythmias. Based on general knowledge and our studies we hypothesize that laterally localized Cx43 channels might transmit signals from cardiomyocytes into extracellular space and by this way contribute to adverse extracellular matrix remodeling. Intention of the project is to reveal the possible implication of Cx43 channels in modulation of extracellular space in diseased heart. It may stimulate to search novel approaches in protection from cardiac dysfunction and arrhythmias.
Duration: 1.1.2020 – 31.12.2023
Použitie hmotnostnej spektrometrie na porovnanie glykoprofilov rôznych kmeňov potkanov v intervencii metabolických porúch
The use of mass spectrometry for comparative study of different rats strains glycoprofiles within metabolic disturbances intervention
Program: VEGA
Project leader: Ing. Brnoliaková Zuzana PhD.
Annotation: Metabolic syndrome (MetS) defines a cluster of interrelated risk factors for diabetes mellitus. Glycobiology ishelping in search for biomarkers of severe diseases, the bioanalytical metods were patented. We hypothesize:the glycomic profiling of blood sera has the potential in MetS diagnostics. The goals are to acquire glycomicprofiles, by means of mass spectrometry, derived from blood sera of different rats strains; to characterize theircomposition; to correlate with pathophysiology; to evaluate the differences with respect to the glycosylationchanges (sialylation, fucosylation). In vivo: to realize the study with nutritional intervention; to evaluate the effectof allimentary habits preferences on the metabolic condition. In vitro: to investigate the impact of key mechanismsof MetS in association with cellular glycoprofile induced changes. As the output: might be the model glycomic toolfor basic research appointed to test therap. approaches with perspespective for clinical researchrecommendations.
Duration: 1.1.2021 – 31.12.2023
Prepojenie niektorých foriem bunkovej smrti nekrotického fenotypu: signalizácia a multicieľový nástroj pre zmiernenie poškodenia srdca v dôsledku ischémie?
Program: VEGA
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Duration: 1.1.2020 – 31.12.2023
SVBENMKVS – Skúmanie vplyvu bakteriálneho endotoxínu na mechanosenzorický komplex v srdci.
Investigation of endotoxin effects on mechanosensoric complex in the heart of normotensive rats.
Program: VEGA
Project leader: RNDr. Okruhlicová Ľudmila CSc.
Annotation:
Duration: 1.12.2020 – 31.12.2023
Štúdium nových mechanizmov kardioprotekcie voči ischemicko-reperfúznemu poškodeniu srdca: úloha extracelulárnych vezikúl, nekódujúcich RNA a vplyv metabolických komorbidít na tieto mechanizmy
Study of new mechanisms of cardioprotection against ischemia-reperfusion injury of the heart: role of extracellular vesicles, non-coding RNAs and impact of metabolic co-morbidities on these mechanisms
Program: VEGA
Project leader: doc. RNDr. Barteková Monika PhD.
Annotation: Ischemic heart disease and myocardial infarction represent major diseases associated with ischemia-reperfusion(I/R) injury of the heart. Despite several powerful cardioprotective interventions against I/R injury includingendogenous (e.g. ischemic conditioning) as well as exogenous ones including treatment with natural antioxidants,have been proposed, molecular mechanisms of cardioprotection are not fully clarified so far; moreover, there areserious translational gaps in transferring cardioprotective interventions into clinics due to comorbidities present inreal patients suffering from cardiac I/R injury. The aim of the present project is to uncover the role of extracellularvesicles as new players in cardioprotection, to identify particular non-coding RNAs involved in cardioprotection,and to explore the effect of metabolic co-morbidities on molecular mechanisms and efficiency of cardioprotection,altogether in the sake of effective transfer of experimental knowledge to human personalized medicine.
Duration: 1.1.2020 – 31.12.2023
Vplyv starnutia a hypertenzie na experimentálny infarkt myokardu
The effect of aging and hypertension on experimental myocardial infarction
Program: VEGA
Project leader: RNDr. Cebová Martina PhD.
Annotation: Myocardial infarction is a serious cardiovascular disease associated with cardiac remodeling as a consequenceof ischemia. Hypertension and aging aggravate the consequences of heart attack by the formation of oxidativeand inflammatory mediators in the heart. Mereover, reperfusion after ischemia creates additional oxidative stresswith a negative effect on myocardial tissue. To monitor the signaling molecules that can block or reverse thepathological process of infarction in hypertension is an important hypothesis for successful treatment ofmyocardial infarction. Therefore, our goal will be to exmine the effect of hypertension and aging on myocardialinfarction and to analyze the effect of nitric oxide production, free oxygen radicals, and pleiotropic transcriptionfactor Nrf2. In particular, the activation of Nrf2 and its target genes in elderly individuals may provide a novelmechanism of protection the myocardium from pathological cardiac remodeling.
Duration: 1.1.2020 – 31.12.2023
Výskum prírodných látok s terapeutickým potenciálom v humánnej medicíne: komplexná analýza, biologické účinky a štúdium synergie.
Program: VEGA
Project leader: Ing. Račková Lucia PhD.
Annotation: Research work in the field of natural sources of antimicrobial active substances from the last two decades confirms the strong potential of natural substances and extracts, both in the eradication of resistant bacteria and fungi, but also in the prevention of biofilm formation and its destruction. The aim of this project is to test the biological activities of selected plant extracts, their secondary metabolites and their semisynthetic derivatives as potential antimicrobial and antibiofilm, as well as antioxidant, antiphlogistic and immunomodulatory agents. At the same time to exclude their cytotoxic potential on human cells in vitro and to evaluate the fingerprint of plant extracts by modern analytical methods. The target site for the action of these substances should be microbes colonizing skin infections (especially poorly healing, burns, surgical / postoperative wounds) and infections of the oral mucosa (especially the root canals of devital teeth and periradicular tissues). Another aim is to create a combination of active substances / extracts (synergistically acting), which will be adjusted to a gel base, which will be enriched with high-purity micronized beta-glucan in order to eradicate microbes on the skin and mucosa and promote tissue regeneration.
Duration: 1.1.2020 – 31.12.2023
TOXINOVAGE – Inovatívne prístupy v toxikológii starnutia
Innovative approaches in toxicology of ageing
Program: SRDA
Project leader: Ing. Račková Lucia PhD.
Duration: 1.7.2019 – 30.6.2023
Štúdium štruktúrnych zmien komplexných glykokonjugátov v procese dedičných metabolických a civilizačných ochorení
The study of structural changes of complex glycoconjugates in the proces of inherited metabolic and civilization diseases
Program: EU Structural Funds Research & Development
Project leader: Ing. Brnoliaková Zuzana PhD.
Duration: 1.3.2021 – 30.6.2023
Úloha matrixových metaloproteináz v patofyziológii ochorení kardiovaskulárneho systému a ich vzťah k bunkovej redoxnej signalizácii.
The role of matrix metalloproteinases in pathophysiology of cardiovascular system diseases and their relation to cellular redox signaling.
Program: SRDA
Project leader: RNDr. Barančík Miroslav DrSc.
Duration: 1.7.2019 – 30.6.2023
Experimentálna štúdia pôsobenia materskej depresie a antidepresívnej liečby počas gravidity a laktácie na zdravie matky a vývin potomstva.
Program: VEGA
Project leader: RNDr. Dubovický Michal CSc.
Annotation:
Duration: 1.1.2019 – 31.12.2022
Experimentálny infarkt myokardu: príspevok hypertenzie a obezity, účinok inhibítora toll-like receptorov.
Program: VEGA
Project leader: doc. RNDr. Pecháňová Oľga DrSc.
Duration: 1.1.2019 – 31.12.2022
Hodnotenie a porovnanie protizápalovej a antioxidačnej účinnosti karotenoidov in vitro a in vivo pomocou modelov chronických zápalových ochorení.
Program: VEGA
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.
Annotation:
Duration: 1.1.2020 – 31.12.2022
Kognitívne a neurofyziologické determinanty sémantickej kognície
Cognitive and neurophysiological determinants of semantic cognition
Program: VEGA
Project leader: Mgr. Marko Martin PhD.
Annotation: Semantic system creates and structures knowledge that guides adaptive cognition and behavior. The ability to access and use relevant semantic information is underpinned by a number of neurocognitive mechanisms, which are poorly understood. Our research aim is to investigate the cognitive systems and mechanisms that regulate the retrieval of information from semantic memory. For this purpose, we will use systematic manipulation of cognitive load and non-invasive transcranial electrical stimulation (tES) of the prefrontal brain cortex. Using these experimental approaches, we will inspect the role of executive control in semantic retrieval and provide a detailed description of the fundamental cognitive and neurophysiological determinants of semantic retrieval functions.
Project web page: https://www.researchgate.net/project/Cognitive-and-neurophysiological-determinants-of-semantic-cognition
Duration: 1.1.2020 – 31.12.2022
Modulácia dysregulácie extracelulárnej matrix a medzibunkovej komunikácie ako protekcia srdcového svalu pred jeho funkčným zlyhaním
Modulation of dysregulation of extracellular matrix and intercellular communication as a heart protection from its functional failure
Program: VEGA
Project leader: RNDr. Szeiffová Bačová Barbara PhD.
Annotation: Cardiovascular diseases are accompanied by extracellular matrix remodeling and fibrosis associated with impaired myocardial gap junction communication, what subsequently results in the development of heart failure and malignant arrhythmias. Cardiac fibrosis is one of the major problems in medicine with no effective treatment. We aimed in this project to characterize key factors involved in profibrotic signaling in rats with hypertension, altered thyroid status, post-infarction injury and to examine the possibilities of pharmacological and non-pharmacological modulation of these profibrotic factors. This approach should reveal key signaling pathways and proteins whose modulation could reverse or stop fibrosis process and then improve intercellular communication in the myocardium. Project results should contribute to new knowledge potentially usable in clinical practice as well.
Duration: 1.1.2019 – 31.12.2022
PROTEKCIA KARDIOVASKULÁRNEHO SYSTÉMU PRI EXPERIMENTÁLNEJ HYPERTENZII A ZLYHANÍ SRDCA DUÁLNOU INHIBÍCIOU NEPRILYZÍNU A AT1 RECEPTOROV PRE ANGIOTENZÍN II: POROVNANIE S ACE-INHIBÍCIOU A MELATONÍNOM
Program: VEGA
Project leader: doc. RNDr. Pecháňová Oľga DrSc.
Duration: 1.1.2019 – 31.12.2022
TraiN-SafeMDs – Školiaca sieť zameraná na zvýšenie bezpečnosti zdravotníckych pomôcok – fokus na ústnu dutinu
Training Network for improving of safety of medical devices – focus on oral cavity
Program: SRDA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation: Medical devices (MDs) have irreplaceable role in modern healthcare. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MDs used in the oral cavity are usually those helping in the treatment of aphthae or canker sores irritations and lesions of the oral mucosa by forming a barrier that adheres to the oral mucosa and promotes healing. Dental materials and dental prosthetic devices are also an important group of MDs with apparent contact with oral mucosa. Most of the MDs bio-compatibility assessments is still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress in validation of alternative methods, the MD regulations are also in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed epidermis test for intra-cutaneous testing into the ISO standard 10993-23 (Kandarova et al.,/DeJong et al., 2018). Biocompatibility testing of MDs is based on the toxicity assessment of extracts from MDs, that are in fact highly diluted solutions of potential irritants. Therefore any already validated in vitro tests and prediction models must be fine-tuned to achieve different levels of sensitivity for this specific type of materials.The proposed project builds on the practical experiences gained in the validation study for intra-cutaneous testing of MDs in which the research teams from Slovakia and Czech republic participated between 2012-2018. The current project will use 3D reconstructed tissues of oral/buccal epithelia and cell cultures with the origin in oral cavity with the aim to develop highly sensitive testing strategy for local tolerance testing in vitro. The project alsoaims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Project web page: medicaldevicessafety.com
Duration: 1.3.2020 – 31.12.2022
Účinky prírodných a syntetických zlúčenín pri oxidačnom poškodení biomakromolekúl. Pro- a antioxidačné mechanizmy.
Effects of natural and synthetic compounds on oxidative damage of biomacromolecules. Pro-oxidative and antioxidative mechanisms.
Program: VEGA
Project leader: RNDr. Valachová Katarína PhD.
Annotation:
Duration: 1.1.2019 – 31.12.2022
Účinok bakteriálneho endotoxínu na komunikačné spojenia ciev srdca za podmienok hypertenzie.
Program: VEGA
Project leader: Ing. Frimmel Karel PhD.
Duration: 1.1.2019 – 31.12.2022
Vazoaktívne účinky sulfidovej signalizácie a jej interakcia s oxidom dusnatým v rôznych animálnych modeloch metabolického syndrómu
Vazoactive effects of hydrogen sulphide signalling pathway and its interaction with nitric oxide in different animal models of metabolic syndrome
Program: VEGA
Project leader: Mgr. Berényiová Andrea PhD.
Annotation: Nitric oxide (NO) and hydrogen sulphide (H2S) are signalling molecules involved into the regulation of the arterial tone. The synthesis of both has been shown in arterial wall, moreover their contribution in physiological (relaxation of arterial smooth muscle cells) and pathophysiological processes (hypertension, diabetes mellitus, atherosclerosis) have been already proved. Metabolic syndrome (MS) is a group of abnormalities including obesity, hypertension, hyperlipidemia which that together increase the risk of developing cardiovascular disease. Studies have characterised H2S signalisation and NO-H2S interaction especially in normotensive rats, information about their role in experimental hypertension are just limited and about their engagement into the etiopathogenesis of metabolic syndrome is totally missing. The main goal of this project is to describe the vasomotoric role of NO and H2S in different models of MS: induced by high-fructose diet, by high-fat diet in normotension and primary hypertension.
Duration: 1.1.2019 – 31.12.2022
Vplyv fruktózovej diéty v experimentálnych modeloch metabolického syndrómu a u zdravých jedincov: návrh účinnej farmakologickej liečby
Effect of fructose diet in experimental models of metabolic syndrome and in healthy subjects: proposal of effective pharmacological treatment
Program: VEGA
Project leader: RNDr. Gáspárová Zdenka PhD.
Annotation: The project will contribute to the knowledge about etiopathogenesis of metabolic syndrome (MetS). It extend the current project, where we study the impact of high-fat and high-fat-high-fructose diet on hypertriacylglycerolemic(HTG) rats. Chronic diseases such as MetS are generally multifactorial. Thus in their origin and development play a role not only environment (diet, physical activity, stress) but also genetic predisposition. In the new project, we will examine effect of fructose diet (FD) on various animal models (spontaneously hypertensive, HTG, Zucker obese/nonobese and Wistar healthy rats) and find which main risk factor of MetS together with FD cause the most serious damage. We will test the effect of the prospective pyridoindole SMe1EC2 and omega-3 fatty acids on the established model. By combining of these drugs, we expect increased effect on a number of risk factors of cardiovascular and cerebrovascular diseases without causing adverse effects, thus a proposal for a new more effective treatment.
Duration: 1.1.2019 – 31.12.2022
Terapia KVO – Vplyv terapie na redoxnú reguláciu, biochemické markery a bunkovú signalizáciu vekovo-závislých kardiovaskulárnych a neurodegeneratívnych ochorení.
Effect of therapy on redox regulation, biochemical markers and cell signaling of age-dependent cardiovascular and neurodegenerative diseases.
Program: VEGA
Project leader: doc. RNDr. Dovinová Ima PhD.
Annotation: In cardiovascular damage, oxidative stress is triggered by an increase in oxidative stress, affecting changes in the activities of SOD / NOS proteins, biochemical markers, metabolites, as well as redox regulation of SERCA Ca2 + -ATPases. Oxidative stress is a regulated antioxidant and detoxification response by activating the transcription factor Nrf2.The nuclear receptor and nutritional factor PPAR gamma is another regulator of signaling pathways that is positively linked to the regulation of Nrf2. PPAR gamma nuclear receptor agonists play an important role in the regulation of cardiovascular and hypertensive diseases.
Duration: 1.1.2020 – 31.12.2022
Deriváty kyseliny 1-indoloctovej ako inhibítory aldózareduktázy: vzťah štruktúry a aktivity
Indole-1-acetic acid derivatives as aldose reductase inhibitors: structure – activity relationships
Program: VEGA
Project leader: Ing. Šoltésová Prnová Marta PhD.
Annotation:
Duration: 1.1.2018 – 31.12.2021
Elektrofyziologické koreláty a determinanty presnosti vizuálnej pracovnej pamäti
Electrophysiological correlates and determinants of visual working memory precision
Program: VEGA
Project leader: MUDr. Riečanský Igor PhD.
Duration: 1.1.2019 – 31.12.2021
Mitochondrie ako kľúčový efektor v procesoch kardioprotektívnych intervencií
Mitochondria as a key effector in processes of cardioprotective intervention
Program: VEGA
Project leader: Ing. Ferko Miroslav PhD.
Annotation:
Duration: 1.1.2018 – 31.12.2021
Nitrózo-sulfidová signálna dráha – nové regulačné vazoaktívne účinky v rôznych modeloch artériovej hypertenzie
Nitroso-sulphide signal pathway – novel regulator vasoactive effects in different types of arterial hypertension
Program: VEGA
Project leader: RNDr. Čačányiová Soňa PhD.
Annotation: Nitric oxide (NO) and hydrogen sulphide (H2S) belong to important gaseous molecules engaged to the regulation of arterial tone in normotensive conditions. NO and H2S interaction includes a formation of new products which are part of an original nitroso-sulphide signalling pathway. Our previous experiments in Wistar rats demonstrated that these new signal molecules triggered a specific vasoactive response, different from the effect evoked by NO and H2S. In condition of arterial hypertension, the vasoactive effects of the novel signalisation have not been described yet. The aim of this project is to characterise the role of NO and H2S as well as of the nitroso-sulphide signalling pathway in different animal models of hypertension: essential (SHR), NO-deficient and also metabolic syndrome (hypertriglyceridemia – HTG). A simultaneous investigation of human vessels isolated from patients with hypertension and dyslipidemia represents an appropriate way how to associate results of basic research with clin. practise.
Duration: 1.1.2018 – 31.12.2021
Nové látky pre prevenciu a terapiu ochorení spôsobených toxicitou glukózy
Novel compounds in prevention and treatment of diseases caused by glucose toxicity
Program: VEGA
Project leader: RNDr. Májeková Magdaléna PhD.
Annotation: In the long term lasting plasma glucose level may affect the course of physiological processes through numerousmetabolic pathways. A polyol pathway ranks among the important mechanisms of glucose toxicity and its mainenzyme – aldose reductase – is a frequent target in design of drugs reducing the progress of chronic diabeticcomplications. Another target could be introduced by calcium homeostasis in cells, as the cytosolic calcium levelis an important factor for many physiological processes, e.g. the insulin secretion. A modulation of calcium pumpSERCA becomes another mechanism for the manifestation of glucose toxicity. The aim of our project is to findnew compounds with polypharmacological effect, by means of combinatorial library of potential aldose reductaseinhibitors and actual knowledge on SERCA activity.
Duration: 1.1.2018 – 31.12.2021
Nové metódy prevencie a liečby oxidačného stresu, ischemicko-reperfúzne poškodenie a transplantácia srdca
Program: Other projects
Project leader: D.h.c., Prof., MUDr. Slezák Ján DrSc., FIACS
Duration: 1.11.2019 – 31.12.2021
ACE2-TXZF – Nové perspektívy v liečbe kardiovaskulárnych komplikácií spojených s COVID-19
New perspectives in the treatment of cardiovascular complications associated with COVID-19
Program: SRDA
Project leader: RNDr. Čačányiová Soňa PhD.
Annotation: Coronavirus disease 2019 (COVID-19), linked to severe acute respiratory syndrome induced by coronavirus-2(SARS-CoV-2), was declared as a global pandemic. While respiratory failure is the major cause of mortality due toCOVID-19, the great number of patients exhibit cardiovascular disorders. Understanding the underlyingmechanisms of cardiovascular complications associated with COVID-19 is of the great importance to reach theeffective therapy and to reduce mortality due to COVID-19. In this project we will imitate the inhibition of ACE2-mediated signalling induced by SARS-Cov-2 using highly specific ACE2 inhibitor MLN-4760. In thispharmacological model of COVID-19 in spontaneously hypertensive rats (SHR) we intend to examine the extend ofMLN-4760-induced vascular damage as well as the mechanisms underlying the action of taxifoline and zofenapril,as perspective pharmacological tools for the treatment of cardiovascular complications associated with COVID-19.TX has been chosen as it was shown as promising drug-like substance inhibiting SARS-Cov-2 replication viainhibition of the main protease (Mpro). ZF is sulfhydryl-containing angiotensin converting enzyme (ACE) inhibitorspontaneously releasing hydrogen sulfide (H2S). Both substances provide several additional cardioprotectiveeffects associated with elevated NO bioavailability and H2S release, respectively. These effects can improvefunction of the cardiovascular system via elevation of NO and H2S-mediated vasodilatation, inhibition oftrombogenesis and induction of antioxidant and antiinflamatory action.
Duration: 16.9.2020 – 31.12.2021
Nové prístupy k liečbe kachexie, zápalu a oxidačného stresu v experimentálnej artritíde: Účinok rôznych rastlinných extraktov z olivových listov, Rhodiola rosea, Tribulus terrestris a extra panenského olivového oleja
Program: VEGA
Project leader: PharmDr. Poništ Silvester PhD.
Annotation:
Duration: 1.1.2019 – 31.12.2021
Ochrana srdca v situáciách nadmernej tvorby kyslikových a nitrozylových radikálov: Molekulárny vodík ako nový potenciálny therapeutický nástroj?
Heart protection in situations of excessive formation of oxygen and nitrosyl radicals: Molecular hydrogen as a new potential therapeutic tool?
Program: VEGA
Project leader: Mgr. Kura Branislav PhD.
Annotation:
Project web page: https://evega.minedu.sk/e-vega/(S(yi1zctb4lxjmuf55ntk1jfbm))/default.aspx
Duration: 1.1.2018 – 31.12.2021
Štúdium spúšťacích faktorov a mechanizmov prenosu signálu indukovaných neinvazívnymi adaptačnými intervenciami v organizme potkana za účelom ochrany myokardu pred schémiou
Study of triggering factors and signal transduction mechanisms induced by noninvasive adaptive interventions in rats aimed to protect myocardium against schemia
Program: VEGA
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation: Cardiovascular diseases are one of the leading causes of mortality in modern society. They are predicted to rise over the coming decades, due to aging population, longer survival of patients after myocardial infarction, and incidence of civilization diseases. Research pointed out to the protective effects of adaptive phenomenon of ischemic preconditioning (IPC) and its novel clinically acceptable and safer forms. Currently, cellular mechanisms activated by stimuli like exercise, acute hypoxia and PC of the remote organ are not yet completely elucidated as compared with classiccal IPC. For that reason, several pathological animal models (myocardial ischemia, hypertension, d. mellitus, dyslipidemia) will be used. Acute and longer lasting adaptive interventions will be tested using relevant methodology (combination of physiological, morphological and biochemical techniques). The results obtained in this project may lead to development of novel or modified therapeutic strategies to manage myocardial ischemia
Duration: 1.1.2018 – 31.12.2021
Vplyv virtuálnej reality na senzorickú reguláciu rovnováhy, fyziologické a psychologické funkcie človeka
The effect of virtual reality on the sensory regulation of balance control, physiological and psychological functions in humans
Program: VEGA
Project leader: Mgr. Hirjaková Zuzana PhD.
Annotation: Virtual reality (VR) is an environment that can be used to assess the postural and psycho-physiologicalparameters of different groups of people. The virtual environment provides an experience close to reality inlaboratory conditions or at home. The aim of the project is to gain new knowledge about the body orientation,sensory regulation of balance control and the level of psycho-physiological stimulation in the VR. The volunteerswill be introduced into the VR and at the same time their postural activity, reactions to vibratory stimulation oflower limb muscles, physiological and psychological level of arousal and stress will be recorded. We assume thatthe project results will provide the basis for designing promising methods for testing sensory balance control andpsycho-physiological reactivity to the virtual environment. The obtained results may be helpful in rehabilitation ofpatients with postural balance disorders as well as people with psychological or physiological difficulties.
Duration: 1.1.2019 – 31.12.2021